Summary: Rare missense variants in the DDX6 gene are linked to a newly recognized neurodevelopmental syndrome. These genetic changes disrupt RNA processing structures in cells and are associated with developmental delays, impaired motor and speech milestones, characteristic facial features, and intellectual disability.
Source: The Translational Genomics Research Institute
Overview
Scientists at the Translational Genomics Research Institute (TGen), an affiliate of City of Hope, led an international effort that identified disease-causing variants in the DDX6 gene. The study, published in the American Journal of Human Genetics, describes how rare de novo missense changes in DDX6 are associated with significant disruption of central nervous system development and a consistent clinical presentation in affected children.
The research links these DDX6 variants to impairments in fundamental skills such as walking and speaking, as well as broader intellectual disability. The discovery emerged from combining clinical genome sequencing, public population databases, and collaboration between clinicians and laboratories across multiple countries.
“One of the most powerful findings of this work is the identification of pathogenic mutations in DDX6, a gene not previously connected with childhood neurodevelopmental disorders,” said Chris Balak, research associate in TGen’s Neurogenomics Division and the study’s lead author. “Our data indicate DDX6 plays a key role in early brain development.”
Balak and colleagues first identified a likely pathogenic DDX6 variant in a five-year-old girl evaluated at TGen’s Center for Rare Childhood Disorders. By comparing her genome to public datasets and to the genomes of her healthy parents, the team recognized this as a de novo event. Following the initial finding and posting of preliminary data on a shared investigator platform, TGen and collaborators identified four additional unrelated patients with highly similar clinical features — two in the United States, and one each in France and the Netherlands.
Clinical features
The five affected children described in the study share a core set of traits: global developmental delay, intellectual disability of varying severity, speech and feeding difficulties, low muscle tone with delayed or impaired walking, specific facial characteristics such as telecanthus and epicanthus, and mild-to-moderate cardiac anomalies in some cases. The consistency of these signs across unrelated patients supports the conclusion that DDX6 variants cause a distinct neurodevelopmental syndrome.
Biological mechanism and laboratory findings
DDX6 encodes an RNA helicase that is a key component of membrane-less cellular structures called processing bodies (P-bodies), which participate in mRNA storage and translational repression. The study reports five rare de novo missense variants clustered within conserved motifs of the RecA-2 domain of DDX6, a region critical for RNA binding and helicase function.
Functional laboratory experiments using patient-derived fibroblasts and model human cell lines demonstrated that several of these variants (including p.Arg373Gln and p.Cys390Arg) cause marked defects in P-body assembly. Immunoprecipitation assays also showed disrupted interactions between mutant DDX6 proteins and several normal binding partners. Complementation experiments incorporating additional variants (p.Thr391Ile and p.Thr391Pro) produced consistent defects in P-body formation, reinforcing the link between molecular dysfunction and the clinical syndrome.
Structural modeling placed these variants near known protein-binding regions, suggesting that altered partner interactions and impaired RNA handling underlie the cellular pathology. Taken together, the clinical observations and molecular data define a DDX6-related neurodevelopmental disorder and add DDX6 to an expanding group of RNA helicase genes implicated in brain development, alongside genes such as DDX3X and DHX30.
Collaboration and impact
This work reflects broad collaboration among institutions, including clinical centers and research laboratories in the United States and Europe. Contributors included teams from the Institute of Genetics and Molecular and Cellular Biology, Sorbonne University, the Broad Institute, Massachusetts General Hospital, Geisinger Medical Center, Cleveland Clinic, and several hospitals and research centers across the Netherlands, Germany, and France.
“By combining genomic sequencing with detailed molecular follow-up using patient cells and tissues, our international team discovered a previously unrecognized neurodevelopmental syndrome caused by DDX6 mutations,” said Dr. Vinodh Narayanan, Medical Director of TGen’s Center for Rare Childhood Disorders and a senior author on the study. “Understanding these disease mechanisms can illuminate related disorders and, in time, inform focused therapeutic strategies.”
Funding
Funding for the study, titled “Rare De Novo Missense Variants in RNA Helicase DDX6 Cause Intellectual Disability and Dysmorphic Features and Lead to P-Body Defects and RNA Dysregulation,” was provided by Foundation Jerome Lejeune, Fondation Maladies Rares, Association Paul and Liba Mandel, CREGEMES, the Agence Nationale de la Recherche (French National Research Agency), and private donors supporting TGen’s Center for Rare Childhood Disorders.
Source:
The Translational Genomics Research Institute
Media Contacts:
Steve Yozwiak – The Translational Genomics Research Institute
Image Source:
The image is in the public domain.
Original Research:
“Rare De Novo Missense Variants in RNA Helicase DDX6 Cause Intellectual Disability and Dysmorphic Features and Lead to P-Body Defects and RNA Dysregulation,” Chris Balak et al., American Journal of Human Genetics.
Abstract (condensed)
DDX6 is an RNA helicase essential for P-body formation and mRNA metabolism. The study reports five rare de novo missense variants located in conserved regions of the RecA-2 domain that impair RNA binding, helicase activity, and protein interactions. Functional assays show these variants disrupt P-body assembly and interaction with protein partners. Clinical data from affected probands link these molecular defects to a consistent neurodevelopmental phenotype, supporting classification of DDX6 as a causative gene for a newly described neurodevelopmental disorder.